Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Open access
Fujii, Takeo, Colen, Rivka R., Bilen, Mehmet Asim, Hess, Kenneth R., Hajjar, Joud, Suarez-Almazor, Maria E., Alshawa, Anas, Hong, David S., Tsimberidou, Apostolia, Janku, Filip, Gong, Jing, Stephen, Bettzy, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Sharma, Padmanee, Mendoza, Tito, Patel, Anisha, Thirumurthi, Selvi, Sheshadri, Ajay, Meric-Bernstam, Funda, Naing, Aung · 2018 · Investigational New Drugs

Abstract

SummaryBackground Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated with unbridled T cell activity remains a concern. Patients and methods A retrospective review of the electronic medical records of 290 patients with advanced cancer treated on an immunotherapy-based clinical trial in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center between February 2010 and September 2015 was performed. Clinical and laboratory parameters were collected to determine the incidence of irAEs, risk factors, and their association with treatment outcomes. Results Ninety eight of 290 patients (34%) experienced any grade irAEs. Among the 15 (5.2%) patients with grade ≥ 3 irAEs, the most common irAEs were dermatitis and enterocolitis. Although 80% of the patients with grade ≥ 3 irAEs required systemic corticosteroids, all the 15 patients recovered from the irAEs. On re-challenge, 4 of the 5 patients who had received systemic corticosteroids for irAE continued to respond. There were no irAE-related deaths. Importantly, patients with grade ≥ 3 irAEs had improved overall response rate (25 vs. 6%; p = 0.039) and longer median time to progression (30 weeks vs. 10 weeks; p = 0.0040) when compared to those without grade ≥ 3 irAEs. Conclusion Incidence of irAEs with immunotherapeutic agents indicates an active immune status, suggestive of potential clinical benefit to the patient. Further validation of this association in a large prospective study is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-017-0534-0

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 179

Metadata

Authors
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A., Janku, F., Gong, J., Stephen, B., Subbiah, V., Piha-Paul, S. A., Fu, S., Sharma, P., Mendoza, T., Patel, A., Thirumurthi, S., Sheshadri, A., Meric-Bernstam, F., & Naing, A.
Venue
Investigational New Drugs
Published
2017-11-21
Volume
36
Issue
4
Pages
638-646
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2768499948
Cited by
179
References
20
FWCI
7.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. https://app.cochat.ai/papers/10.1007/s10637-017-0534-0
The paper
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A., Janku, F., Gong, J., Stephen, B., Subbiah, V., Piha-Paul, S. A., Fu, S., Sharma, P., Mendoza, T., Patel, A., Thirumurthi, S., . . . Naing, A. (2018). Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs. https://doi.org/10.1007/s10637-017-0534-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.